[
    {
        "n":  1,
        "id":  "slide-1",
        "title":  "Slide 1 - Mudancas de Paradigma no Tratamento da Osteoporose",
        "file":  "S01_slide-01.html"
    },
    {
        "n":  2,
        "id":  "slide-2",
        "title":  "Slide 2 - CitaÃ§Ã£o Rilke",
        "file":  "S02_slide-02.html"
    },
    {
        "n":  3,
        "id":  "slide-3",
        "title":  "Slide 3 - Objetivos Educacionais",
        "file":  "S03_slide-03.html"
    },
    {
        "n":  4,
        "id":  "slide-4",
        "title":  "Slide 4 - De onde vem estas recomendacoes?",
        "file":  "S04_slide-04.html"
    },
    {
        "n":  5,
        "id":  "slide-5",
        "title":  "Slide 5 - Evolucao do conceito",
        "file":  "S05_slide-05.html"
    },
    {
        "n":  6,
        "id":  "slide-6",
        "title":  "Slide 6 - Trials Pivotais",
        "file":  "S06_slide-06.html"
    },
    {
        "n":  7,
        "id":  "slide-utilidade-comparada",
        "title":  "Slide 6A - Utilidade Comparada: Fraturas vs DoenÃ§as",
        "file":  "S07_slide-07.html"
    },
    {
        "n":  8,
        "id":  "slide-8",
        "title":  "Slide 8 - O que e Utilidade em Saude",
        "file":  "S08_slide-08.html"
    },
    {
        "n":  9,
        "id":  "slide-12",
        "title":  "Slide 12 - Quanto uma fratura â€œcustaâ€ em qualidade de vida?",
        "file":  "S09_slide-09.html"
    },
    {
        "n":  10,
        "id":  "slide-qaly-por-risco",
        "title":  "Slide 12A - QALY por risco: por que o risco basal muda tudo",
        "file":  "S10_slide-10.html"
    },
    {
        "n":  11,
        "id":  "slide-qaly-limiar-paises",
        "title":  "Slide 12B - Quanto vale 1 QALY? Limiar por paÃ­s",
        "file":  "S11_slide-11.html"
    },
    {
        "n":  12,
        "id":  "slide-9",
        "title":  "Slide 9 - IncidÃªncia de fraturas por sÃ­tio e sexo (EU27+2, 2019)",
        "file":  "S12_slide-12.html"
    },
    {
        "n":  13,
        "id":  "slide-9-osteopenia",
        "title":  "Slide 9B - Paradoxo das Fraturas em Osteopenia",
        "file":  "S13_slide-13.html"
    },
    {
        "n":  14,
        "id":  "slide-7",
        "title":  "Slide 7 - Caso ClÃ­nico",
        "file":  "S14_slide-14.html"
    },
    {
        "n":  15,
        "id":  "slide-frax-diabetes-1",
        "title":  "A Armadilha do FRAX no Diabetes",
        "file":  "S15_slide-15.html"
    },
    {
        "n":  16,
        "id":  "slide-frax-diabetes-2",
        "title":  "FRAX no Diabetes: Diretrizes e Ajustes",
        "file":  "S16_slide-16.html"
    },
    {
        "n":  17,
        "id":  "slide-13",
        "title":  "Slide 13 - Modelos FRAX",
        "file":  "S17_slide-17.html"
    },
    {
        "n":  18,
        "id":  "slide-14",
        "title":  "Slide 14 - FRAX-Brasil 2.0 e SPAH: calibraÃ§Ã£o brasileira",
        "file":  "S18_slide-18.html"
    },
    {
        "n":  19,
        "id":  "slide-15",
        "title":  "Slide 15 - DM2 e obesidade: quando o FRAX subestima",
        "file":  "S19_slide-19.html"
    },
    {
        "n":  20,
        "id":  "slide-17",
        "title":  "Slide 17 - Quanto maior o risco basal, maior o ganho",
        "file":  "S20_slide-20.html"
    },
    {
        "n":  21,
        "id":  "slide-18",
        "title":  "Slide 18 - NOGG 2024: Limiares Idade-Dependentes",
        "file":  "S21_slide-21.html"
    },
    {
        "n":  22,
        "id":  "slide-19",
        "title":  "Slide 19 - ClassificaÃ§Ã£o PrÃ¡tica de Risco",
        "file":  "S22_slide-22.html"
    },
    {
        "n":  23,
        "id":  "slide-20",
        "title":  "Slide 20 - Risco Iminente",
        "file":  "S23_slide-23.html"
    },
    {
        "n":  24,
        "id":  "slide-21",
        "title":  "Slide 21 - Risco iminente: a janela crÃ­tica",
        "file":  "S24_slide-24.html"
    },
    {
        "n":  25,
        "id":  "slide-22",
        "title":  "Slide 22 - Risco de refratura em 12 meses por sÃ­tio",
        "file":  "S25_slide-25.html"
    },
    {
        "n":  26,
        "id":  "slide-23",
        "title":  "Slide 23 - Quando fazer anabÃ³lico primeiro",
        "file":  "S26_slide-26.html"
    },
    {
        "n":  27,
        "id":  "slide-24",
        "title":  "Slide 24 - Blunting Effect",
        "file":  "S27_slide-27.html"
    },
    {
        "n":  28,
        "id":  "slide-25",
        "title":  "Slide 25 - Treat-to-target: 3 metas de T-score",
        "file":  "S28_slide-28.html"
    },
    {
        "n":  29,
        "id":  "slide-26",
        "title":  "Slide 26 - Ponto de partida por esquema",
        "file":  "S29_slide-29.html"
    },
    {
        "n":  30,
        "id":  "slide-27",
        "title":  "Slide 27 - Matriz T-score x escolha da droga inicial",
        "file":  "S30_slide-30.html"
    },
    {
        "n":  31,
        "id":  "slide-28",
        "title":  "Slide 28 - Romosozumabe (Evenity) no SUS",
        "file":  "S31_slide-31.html"
    },
    {
        "n":  32,
        "id":  "slide-29",
        "title":  "Slide 29 - [Divisor conceitual]",
        "file":  "S32_slide-32.html"
    },
    {
        "n":  33,
        "id":  "slide-30",
        "title":  "Slide 30 - ReduÃ§Ã£o de mortalidade com zoledronato",
        "file":  "S33_slide-33.html"
    },
    {
        "n":  34,
        "id":  "slide-31",
        "title":  "Slide 31 - Zoledronato Reduz Mortalidade?",
        "file":  "S34_slide-34.html"
    },
    {
        "n":  35,
        "id":  "slide-32",
        "title":  "Slide 32 - Esse Achado Foi Replicado?",
        "file":  "S35_slide-35.html"
    },
    {
        "n":  36,
        "id":  "slide-33",
        "title":  "Slide 33 - Time to benefit",
        "file":  "S36_slide-36.html"
    },
    {
        "n":  37,
        "id":  "slide-34",
        "title":  "Slide 34 - Quando NAO tratar",
        "file":  "S37_slide-37.html"
    },
    {
        "n":  38,
        "id":  "slide-35",
        "title":  "Slide 35 - Algoritmo Treat-to-Target em 5 Passos",
        "file":  "S38_slide-38.html"
    },
    {
        "n":  39,
        "id":  "slide-36",
        "title":  "Slide 36 - Take Home Points",
        "file":  "S39_slide-39.html"
    },
    {
        "n":  40,
        "id":  "slide-37",
        "title":  "Slide 37 - Conceitos de EBM",
        "file":  "S40_slide-40.html"
    },
    {
        "n":  41,
        "id":  "slide-38",
        "title":  "Slide 38 - CitaÃ§Ã£o Rilke (DragÃµes)",
        "file":  "S41_slide-41.html"
    },
    {
        "n":  42,
        "id":  "slide-39",
        "title":  "Slide 39 - Osteoporose Induzida por Glicocorticoides",
        "file":  "S42_slide-42.html"
    },
    {
        "n":  43,
        "id":  "slide-40",
        "title":  "Slide 40 - Risco de Fratura Vertebral por Dose de GC",
        "file":  "S43_slide-43.html"
    },
    {
        "n":  44,
        "id":  "slide-41",
        "title":  "Slide 41 - Caso Clinico",
        "file":  "S44_slide-44.html"
    },
    {
        "n":  45,
        "id":  "slide-42",
        "title":  "Slide 42 - O que cada diretriz recomendaria para Maria?",
        "file":  "S45_slide-45.html"
    },
    {
        "n":  46,
        "id":  "slide-43",
        "title":  "Slide 43 - Evidencias e Populacoes Especiais",
        "file":  "S46_slide-46.html"
    },
    {
        "n":  47,
        "id":  "slide-44",
        "title":  "Slide 44 - Classificacao de Risco ACR 2022",
        "file":  "S47_slide-47.html"
    },
    {
        "n":  48,
        "id":  "slide-45",
        "title":  "Slide 45 - Evidencias e Avaliacao de Risco",
        "file":  "S48_slide-48.html"
    },
    {
        "n":  49,
        "id":  "slide-46",
        "title":  "Slide 46 - Classificacao de Risco e Tratamento ECTS 2024",
        "file":  "S49_slide-49.html"
    },
    {
        "n":  50,
        "id":  "slide-47",
        "title":  "Slide 47 - Diretriz JSBMR 2023 -- Sistema de PontuaÃ§Ã£o",
        "file":  "S50_slide-50.html"
    },
    {
        "n":  51,
        "id":  "slide-48",
        "title":  "Slide 48 - TBS: InterpretaÃ§Ã£o e Ajuste do FRAX",
        "file":  "S51_slide-51.html"
    },
    {
        "n":  52,
        "id":  "slide-49",
        "title":  "Slide 49 - DIOP: quando o remedio vira fratura -- osso vs quedas",
        "file":  "S52_slide-52.html"
    },
    {
        "n":  53,
        "id":  "slide-50",
        "title":  "Slide 50 - DIOP (1/2): classes comuns + armadilhas MBE",
        "file":  "S53_slide-53.html"
    },
    {
        "n":  54,
        "id":  "slide-51",
        "title":  "Slide 54",
        "file":  "S54_slide-54.html"
    },
    {
        "n":  55,
        "id":  "slide-52",
        "title":  "Slide 52 - MBE: PPI -- associaÃ§Ã£o consistente, causalidade incerta",
        "file":  "S55_slide-55.html"
    },
    {
        "n":  56,
        "id":  "slide-53",
        "title":  "Slide 56",
        "file":  "S56_slide-56.html"
    },
    {
        "n":  57,
        "id":  "slide-54",
        "title":  "Slide 57",
        "file":  "S57_slide-57.html"
    },
    {
        "n":  58,
        "id":  "slide-55",
        "title":  "Slide 55 - Vitamina D e quedas: beneficio incerto; bolus alto pode aumentar quedas",
        "file":  "S58_slide-58.html"
    },
    {
        "n":  59,
        "id":  "slide-56",
        "title":  "Slide 56 - Dose diaria vs semanal de vitamina D: 25(OH)D â†’ queda",
        "file":  "S59_slide-59.html"
    },
    {
        "n":  60,
        "id":  "slide-57",
        "title":  "Slide 57 - VFA: a fratura vertebral que ninguem viu",
        "file":  "S60_slide-60.html"
    },
    {
        "n":  61,
        "id":  "slide-58",
        "title":  "Slide 58 - ApÃªndice -- Reacao de fase aguda ao zoledronato (APR)",
        "file":  "S61_slide-61.html"
    },
    {
        "n":  62,
        "id":  "slide-59",
        "title":  "Slide 59 - ApÃªndice -- Como reduzir sintomas da APR (e manter adesao)",
        "file":  "S62_slide-62.html"
    },
    {
        "n":  63,
        "id":  "slide-60",
        "title":  "Slide 60 - Efeitos adversos raros: AFF e MRONJ",
        "file":  "S63_slide-63.html"
    },
    {
        "n":  64,
        "id":  "slide-61",
        "title":  "Slide 61 - Drug Holiday: quando pausar, quando NAO pausar",
        "file":  "S64_slide-64.html"
    },
    {
        "n":  65,
        "id":  "slide-62",
        "title":  "Slide 62 - Sequenciamento de terapias: 3 armadilhas que mudam desfechos",
        "file":  "S65_slide-65.html"
    },
    {
        "n":  66,
        "id":  "slide-63",
        "title":  "Slide 63 - CTX e P1NP: como coletar e interpretar",
        "file":  "S66_slide-66.html"
    },
    {
        "n":  67,
        "id":  "slide-64",
        "title":  "Slide 64 - Armadilhas, limitacoes e mensagens-chave BTMs",
        "file":  "S67_slide-67.html"
    },
    {
        "n":  68,
        "id":  "slide-66",
        "title":  "Slide 66 - DXA da coluna: artefatos + regra ISCD",
        "file":  "S68_slide-68.html"
    },
    {
        "n":  69,
        "id":  "slide-66",
        "title":  "Slide 66 - DXA da coluna: artefatos + regra ISCD",
        "file":  "S69_slide-69.html"
    },
    {
        "n":  70,
        "id":  "slide-67",
        "title":  "Slide 67 - Monitoramento: LSC define mudanÃ§a real",
        "file":  "S70_slide-70.html"
    },
    {
        "n":  71,
        "id":  "slide-68",
        "title":  "Slide 68 - DiscordÃ¢ncia + quando usar rÃ¡dio 33%",
        "file":  "S71_slide-71.html"
    },
    {
        "n":  72,
        "id":  "slide-romosozumabe-custo",
        "title":  "Slide A1 - Romosozumabe: AnÃ¡lise Custo-Efetividade",
        "file":  "S72_slide-72.html"
    }
]
